Delivery Order SPE2DB22D9316-SPE2DB25FYM39
Award Date
10/11/24
Potential Completion Date
11/4/24
Potential Value
$5.2K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $10,316.36 firm fixed-price delivery order covers the supply of Tysabri 300 mg/15 ml vial, with an ultimate completion date of October 31, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group to provide a comprehensive...
The Defense Logistics Agency (DLA) awarded a $51,581.80 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of TYSABRI 300 MG/15 ML VIAL 15ML. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB24FPQG7, valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support military medical facilities. DMS Pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $41,265.44 firm fixed-price delivery order is for the supply of TYSABRI 300 MG/15 ML vials to support the recurring medical needs of military health facilities. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the...
This federal contract award, valued at $15,474.54, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Tysabri 300 mg/15 ml vials. The contract is a firm fixed-price delivery order with no set-aside designation. It is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This federal contract award is for the delivery of the pharmaceutical drug TYSABRI 300 MG/15 ML VIAL 15ML to the Defense Logistics Agency (DLA). The $48,796.40 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. DMS Pharmaceutical Group has a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the provision of TYSABRI 300 MG/15 ML VIAL 15ML, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, awarded by the Defense Logistics Agency (DLA), a defense agency, with a ceiling value of $10,316.36 and an ultimate completion date of April 9, 2024. The contract has no set-aside designation. This award is part of a larger indefinite delivery contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $48,796.40 firm fixed-price delivery order is for the supply of TYSABRI 300 mg/15 ml vial, a specialized pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $51,581.80 contract is for the delivery of TYSABRI 300 MG/15 ML vials to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which allows...
This federal contract award, identified as SPE2DX15D9168|SPE2DX25F6WVV, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,158.18 firm fixed-price delivery order is for the supply of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product, with a performance period through December 11, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $52,912.40 firm fixed-price delivery order is for the provision of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program....